10.45 0.00 (0.00%)
After hours: 4:00PM EDT
|Bid||5.70 x 800|
|Ask||12.19 x 800|
|Day's Range||10.10 - 10.61|
|52 Week Range||9.21 - 17.83|
|Beta (3Y Monthly)||0.53|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 6, 2017 - Nov 10, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||22.88|
If you're interested in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE), then you might want to consider its beta (a...
Concert (CNCE) delivered earnings and revenue surprises of 15.22% and -83.67%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Concert Pharmaceuticals, Inc. today announced that it will report its second quarter 2019 financial results on Thursday, August 1, 2019, before the U.S. financial markets open.
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...
Concert Pharma (CNCE) reports favorable data from the two early-stage studies on its pipeline candidate, CTP-692, currently under evaluation as an adjunctive treatment for schizophrenia. Share rise.
Concert Pharmaceuticals, Inc. (CNCE) today reported positive results from two studies in its Phase 1 program evaluating CTP-692, a novel deuterium-modified form of D-serine being developed as an adjunctive treatment for schizophrenia. Despite evidence of benefit in multiple published clinical studies of non-deuterated D-serine in the treatment of schizophrenia, its use has been limited due to renal safety concerns. Furthermore, in contrast to non-deuterated D-serine, which has been reported to display highly variable pharmacokinetic behavior in humans, CTP-692 was found to have low inter-individual pharmacokinetic variability.
Concert Pharmaceuticals, Inc. (CNCE) today announced that it has completed patient enrollment of an open label clinical trial to evaluate once-daily compared to twice-daily oral dosing of CTP-543 in patients with alopecia areata. The trial is designed to inform on the optimal dosing regimen for CTP-543 for future clinical trials. Topline data from the dose regimen trial is expected in the fourth quarter of 2019.
Concert Pharmaceuticals, Inc. (CNCE) today announced that it has initiated a second open label clinical trial to evaluate once-daily compared to twice-daily oral dosing of CTP-543 in patients with alopecia areata. Patients in the trial will be randomized to receive either 12 mg twice-daily or 24 mg once-daily of CTP-543 over a 24 week treatment period. This new dose regimen trial is designed to complement the first open label trial initiated by Concert in March 2019, which is ongoing in patients randomized to receive either 8 mg twice-daily or 16 mg once-daily of CTP-543 over a 24 week treatment period.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Roger Tung has been the CEO of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) since 2006. Thi...
The Lexington, Massachusetts-based company said it had a loss of 93 cents per share. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
Concert Pharmaceuticals, Inc. (CNCE) announced today that Jesper Høiland has been appointed to its Board of Directors and will serve as a member of its Compensation Committee, effective immediately. “We are delighted to welcome Jesper to our Board of Directors,” said Roger Tung, Ph.D., President and Chief Executive Officer of Concert Pharmaceuticals. “He is a highly accomplished executive with current management experience as President and CEO of Radius Health, a biopharmaceutical company, and previously served as President and Executive Vice President, Novo Nordisk Inc. USA, where his expertise in product launches and management were instrumental in growing Novo to become the 15th largest pharmaceutical company worldwide.
Concert (CNCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Concert Pharmaceuticals, Inc. (CNCE) today announced that it will report its first quarter 2019 financial results on Thursday, May 2, 2019, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m. ET to discuss first quarter financial results and provide a business update. A live webcast of the first quarter financial results may be accessed in the Investors section of the Company’s website at www.concertpharma.com.
Concert Pharmaceuticals (CNCE) announces initiation of multiple-ascending dose phase I study to evaluate its pipeline candidate, CTP-692, as an adjunctive treatment for schizophrenia.
Concert Pharmaceuticals, Inc. (CNCE) today announced that interim clinical data from its CTP-543 Phase 2 trial in alopecia areata will be presented in a poster presentation and a sponsored lecture at the 11th Annual World Congress for Hair Research (WCHR) being held April 24-27, 2019 in Sitges, Barcelona.
Concert Pharmaceuticals, Inc. (CNCE) today announced that it has initiated an additional trial in the Phase 1 program evaluating CTP-692, a novel deuterium-modified form of D-serine being developed as an adjunctive treatment for schizophrenia. The Phase 1 multiple-ascending dose trial will evaluate the safety, tolerability, and pharmacokinetic profile of CTP-692 in healthy volunteers. “The Phase 1 studies evaluating the dosing and safety of CTP-692 are expected to support advancement into an efficacy study in patients with schizophrenia later this year.
Concert Pharmaceuticals, Inc. (CNCE) today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued a final written decision in connection with the inter partes review (IPR) of U.S. Patent No. 9,249,149 (the ‘149 patent). While PTAB found that the claims of the '149 patent are not patentable, the IPR decision is appealable to the U.S. Court of Appeals for the Federal Circuit, and Concert remains committed to defending the ‘149 patent.